Anaptysbio (ANAB) Gains from Investment Securities (2016 - 2025)

Anaptysbio has reported Gains from Investment Securities for 9 years, with the latest figure at $1.5 million in Q1 2025.

• For the quarter ending Q1 2025, Gains from Investment Securities fell 80.66% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (down 80.66% YoY), and the FY2025 full-year result was $6.9 million, up 13.33% from the prior year.
• Gains from Investment Securities for Q1 2025 stood at $1.5 million, down from $40.2 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $40.2 million in Q4 2024, with the low at -$24.8 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged $536071.4 across 5 years, with a median of -$2.9 million in 2021.
• The largest YoY upside for Gains from Investment Securities was 273.06% in 2024 against a maximum downside of 468.47% in 2024.
• Anaptysbio's Gains from Investment Securities stood at -$1.5 million in 2021, then surged by 831.88% to $10.7 million in 2022, then fell by 18.91% to $8.7 million in 2023, then soared by 362.24% to $40.2 million in 2024, then slumped by 96.39% to $1.5 million in 2025.
• The last three Gains from Investment Securities figures came in at $1.5 million (Q1 2025), $40.2 million (Q4 2024), and -$15.4 million (Q3 2024), per Business Quant data.